The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    April 2020

  • Pages
    281

  • View Count
    6002

Example Insights

China-Biopharmaceutical-Contract-Manufacturing-Context China-Biopharmaceutical-Contract-Manufacturing-List-of-CMOs China-Biopharmaceutical-Contract-Manufacturing-Various-scales
China-Biopharmaceutical-Contract-Manufacturing-Capacity-analysis China-Biopharmaceutical-Contract-Manufacturing-Partnerships-and-collaborations China-Biopharmaceutical-Contract-Manufacturing-Benchmarking
China-Biopharmaceutical-Contract-Manufacturing-Market-forecast    

 

Overview

China represents nearly 18% of the global population. Studies indicate that the Chinese pharmaceutical market is the second largest in terms of annual pharmaceutical revenues, and is estimated to generate more than 10% of the global sales. Till date, over 25 biologics and biosimilar products have been approved in China. In addition, close to 1,000 clinical trials, investigating a variety of biologics and biosimilars for treating a diverse range of diseases, are presently underway in this region. The growing pipeline, coupled to an increasing demand for biopharmaceuticals, has compelled industry stakeholders to enlist the help of capable contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). Due to benefits, such as low labor costs, access to a large indigenous consumer base and a relatively less stringent regulatory environment, several players have demonstrated the preference to partner with contract service providers based in China. 

The biopharmaceutical contract manufacturing market in China presently features a mix of large, mid-sized and small players, some of which offer end-to-end solutions, ranging from development and clinical trial services to commercial manufacturing and regulatory consulting. Additionally, in order to attract more foreign clients and stay ahead within a competitive environment, Chinese CMOs are actively expanding their manufacturing related capabilities and capacities. This has led to the establishment of several partnerships and strategic acquisitions. 

The novel Coronavirus outbreak in China has resulted in immediate disruptions / slow-down in global pharma / biopharma supply chains. In the short-term, it is anticipated to substantially impact the global contract manufacturing market, specifically those countries that have opted to lockdown. However, in the longer term, we remain bullish on the industry’s growth prospects as we expect biopharma companies to resume normal operations after the COVID-19 pandemic is put under control.

Scope of the Report

The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies offering contract manufacturing services for biopharmaceuticals in China, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities, as well as location of these facilities, type of business segment, type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, stability studies, quality assurance and control, scale-up, downstream processing, regulatory support, data analytics and reporting, and others), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression system(s) used (mammalian, microbial and others), type of bioreactor(s) used (single-use bioreactors and stainless steel bioreactors) and its mode of operation (batch, fed-batch and perfusion), type of packaging, and affiliations to regulatory accreditations and certifications (if any).  
  • An analysis of the various partnerships pertaining to biopharmaceutical manufacturing in China, which have been established since 2016, based on several parameters, such as the year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area of the deal, target indication, most active players (in terms of number of partnerships signed), and geography.
  • An analysis of the various expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, over the period 2016-2020 (till February), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
  • A clinical trial analysis of completed and active studies related to biopharmaceuticals that have been / are being / are likely to be conducted in China, based on trial registration year, trial phase, trial recruitment status, type of sponsor / collaborator, geography and number of patients enrolled.
  • An estimate of the overall, installed capacity for manufacturing biopharmaceuticals, based on data reported by industry stakeholders in the public domain; it highlights the distribution of available biopharmaceutical production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), key geographical regions (China, Hong-Kong, Taiwan) and expression system used. 
  • A review of recent initiatives undertaken by big pharma players in China for the manufacturing of biopharmaceuticals, highlighting trends across various parameters, such as number of initiatives, year of initiative, and benchmark analysis of big pharma players.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biopharmaceutical products. Each profile features an overview of the company, its financial performance (if available), information on its service portfolio, details related to manufacturing capabilities and facilities, recent developments (partnerships and expansions), and an informed future outlook.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics. 

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the biopharmaceutical contract manufacturing market in China. Based on various parameters, such as projected growth of the overall biopharmaceutical market in China, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), [B] types of expression systems used (mammalian, microbial and others), [C] scale of operation (preclinical, clinical and commercial), [D] company size (small, mid-sized and large / very large), and [E] type of biologic (antibody, vaccine and others). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biopharma
  • Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
  • Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
 

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the biopharmaceutical contract manufacturing market in China and its likely evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. It also includes information on the various expression systems used for the development of different types of biotherapeutic products. The chapter features a brief overview of the contract manufacturing scenario in China and includes a detailed discussion on the need for outsourcing within the biopharmaceutical industry. Further, we have presented a list of commonly outsourced biomanufacturing activities. The chapter concludes with a discussion on the advantages and challenges that are currently associated with this market.

Chapter 4 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.

Chapter 5 provides an overview of the China biopharmaceutical contract manufacturing landscape. It includes information on close to 40 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such 
such as year of establishment, company size, scale of operation, location of headquarters, number of manufacturing facilities, as well as location of these facilities, type of business segment, type of manufacturing service(s) offered, type of biologic(s) manufactured, type of expression system(s) used, type of bioreactor(s) used, and its mode of operation, type of packaging and affiliations to regulatory accreditations and certifications.   

Chapter 6 features detailed profiles of key industry players that offer various contract manufacturing services at different scales of operation. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.

Chapter 7 features an elaborate analysis of the various partnerships and collaborations that have been inked amongst players in this domain, in the time period 2016-2020 (till February). It provides a brief description on the various types of partnership model (which include manufacturing agreements, mergers / acquisitions, product development agreements, service alliances, and others) that have been adopted by stakeholders in this domain. Further, it includes analyses based on the year of agreement, partnership model, scale of operation, type of biologic, focus area of the deal, target indication and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 8 presents detailed analysis on the various expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, over the period 2016-2020(till February). It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion, and new facility), scale of operation of manufacturing facility, type of biologic, location of manufacturing facility.

Chapter 9 presents a detailed clinical trial analysis of completed and active related to biopharmaceuticals, highlighting prevalent trends across several relevant parameters, such as trial registration year, phase of development, type of biologic, current trial recruitment status, study focus area, key therapeutic areas (in terms of number of trials undertaken / conducted), enrolled patient population and trial location, and leading industry and non-industry players (in terms of number of trials undertaken / conducted).

Chapter 10 provides an overview of various recent developments that have been undertaken in different provinces namely, northern China, eastern China, southern China. Thus, depicting the emerging strength of the contract peptide manufacturers in different regions.

Chapter 11 features an analysis of the overall, installed capacity for manufacturing biopharmaceutical therapeutics / drugs in China based on data reported by industry stakeholders in the public domain; it highlights the distribution of available biopharmaceutical production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), key geographical regions (China, Hong-Kong, Taiwan) and expression system used.

Chapter 12 highlights the recent initiatives undertaken by big pharma players in China for the manufacturing of biopharmaceuticals, highlighting trends across various parameters, such as number of initiatives, year of initiative, and benchmark analysis of big pharma players.

Chapter 13 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of CMOs.

Chapter 14 presents a detailed market forecast analysis, highlighting the likely growth of the China biologics manufacturing market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), [B] types of expression systems (mammalian, microbial and others), [C] scale of operation (preclinical, clinical and commercial), [D] size of the company (small-sized, mid-sized and large / very large), and [E] type of biologic (antibody, vaccine and others).

Chapter 15 provides a detailed analysis on the impact of the COVID-19 pandemic on the businesses of biopharmaceutical contract service providers in China.

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of contract manufacturing market in China, under a SWOT framework.

Chapter 17 highlights the emerging trends and potential market drivers for China biopharmaceutical contract manufacturers. It highlights the various opportunities associated with the growing biopharmaceutical drugs / therapies pipeline, increase in outsourcing of aseptic manufacturing operations, adoption of innovative technologies and increasing opportunities in China, which are likely to impact the evolution of the market in the coming years.

Chapter 18 is a collection of survey interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interview held with Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biopharma), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences) and Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies).

Chapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Manufacturing of Biopharmaceuticals
3.3.1. Types of Expression Systems Used
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Yeast Expression Systems
3.3.1.3. Insect Expression Systems
3.3.1.4. Plant Expression Systems
3.3.1.5. Mammalian Expression Systems
3.3.1.6. Fungal Expression Systems

3.3.2. Processing Steps
3.3.2.1. Upstream Processing
3.3.2.2. Downstream Processing

3.4. Overview of Contract Manufacturing
3.4.1. Contract Manufacturing Scenario in China
3.5. Need for Outsourcing in the Biopharmaceutical Industry
3.5.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry

3.7. Basic Guidelines for Selecting a CMO Partner
3.8. Advantages of Outsourcing Manufacturing Services
3.8.1. Benefits of Engaging Chinese Contract Service Providers
3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
3.9.1. Challenges Associated with Engaging Chinese Contract Service Providers
3.10. Future Perspective

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manuafcturing-Related Challenges

5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Location of Headquarters
5.2.5. Analysis by Location of Manufacturing Fcailities
5.2.6. Analysis by Type of Product
5.2.7. Analysis by Types of Services Offered
5.2.8. Analysis by Type of Biologic 
5.2.9. Analysis by Expression System Used
5.2.10. Analysis by Type of Bioreactor Used
5.2.11. Analysis by Mode of Operation of Bioreactor
5.2.12. Analysis by Packaging Form Used
5.2.13. Analysis by Regulatory Accreditations / Certifications

6. COMPANY PROFILES
6.1 Chapter Overview
6.2 ChemPartner Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.2.1. Cell Line Development
6.2.2.2. Process Development
6.2.2.3. Formulation Development
6.2.2.4. Aseptic Filling and Freeze Drying
6.2.2.5. Drug Developability and Manuafcturing Study
6.2.2.6. Container Extractables and Leachables Study
6.2.2.7. Analytical Development and Testing

6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Recent Developments and Future Outlook

6.3. JHL Biotech
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.2.1. Cell Line and Process Development
6.3.2.2. Analytical and Formulation Development
6.3.2.3. cGMP Manufacturing
6.3.2.4. Quality Systems
6.3.2.5. Regulatory Support
6.3.2.6. Project Management Services

6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Recent Developments and Future Outlook

6.4. JOINN Biologics
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.2.1. Development Services
6.4.2.2. Manufacturing Services
6.4.2.3. Fill / Finish Services
6.4.2.4. Quality Assurance and Quality Control

6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Recent Developments and Future Outlook

6.5 MabPlex
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.2.1. Development Services
6.5.2.2. GMP Manufacturing Services

6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Recent Developments and Future Outlook

6.6. Mycenax Biotech
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.2.1. Cell Development Services
6.6.2.2. Process Development Services
6.6.2.3. Analytical and Quality Control
6.6.2.1. GMP Manuafacturing Services

6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Recent Developments and Future Outlook

6.7. WuXi AppTec
6.7.1. Company Overview
6.7.2 Financial Information

6.7.3. Service Portfolio
6.7.3.1. Discovery Sciences
6.7.3.2. Development Services
6.7.3.3. Testing Services
6.7.3.4. Clinical Manufacturing Services
6.7.3.5. Commercial Manufacturing Services
6.7.3.6. Fill / Finish Operations

6.7.4. Manufacturing Facilities and Capabilities
6.7.5. Recent Developments and Future Outlook

7. PARTNERSHIPS
7.1 Chapter Overview
7.2. Partnership Models
7.3. Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Therapeutic Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.8.1. Geographical Distribution by Number of Partnerships
7.3.8.2. Intercontinental and Intracontinental Agreements

8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
8.2.5. Analysis by Location of Expansion Project
8.2.6. Analysis by Capacity of Expanded Facility
8.2.7. Most Active Players: Analysis by Number of Expansions
8.2.8. Analysis by Region

9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3 Clinical Trial Analysis: Biologic Drugs 
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase 
9.3.3. Analysis by Trial Status
9.3.4. Geographical Analysis by Number of Clinical Trials
9.3.5. Geographical Analysis by Enrolled Patient Population
9.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
9.3.7. Analysis of Enrolled Patient Population by Trial Phase
9.3.8. Analysi by Type of Sponsor / Collaborator
9.3.9. Most Active Players: Analysis by Number of Registered Trials
9.3.10. Analysis by Clinical Trial Center

10. REGIONAL CAPABILITY ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Overall Landscape of Chinese Biopharmaceuticals Contract Manufacturers
10.4. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern China
10.5. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China
10.6. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China
10.7. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern China

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Chinese Biopharmaceutical Contract Manufactures: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Expression System Used
11.3.4. Analysis by Location of Manufacturing Facility
11.3.5. Analysis by Company Size and Location of Manufacturing Facility
11.3.6. Analysis by Scale of Operation and Location of Manufacturing Facility
11.4. Concluding Remarks

12. BIG PHARMA BIOPHARMACEUTICAL MANUFACTURING INITIATIVES IN CHINA
12.1. Chapter Overview
12.2. List of Biopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Players in China
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Year of Initiative
12.2.3. Analysis by Company and Year of Initiative
12.2.4. Analysis by Type of Initiative
12.2.5. Analysis by Type of Biologic

12.3. Competitive Benchmarking of Big Pharmaceutical Players
12.3.1. Harvey Ball Analysis: Big Pharma Investment Summary
12.3.2. Geographical Analysis by Investment Made

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
13.1. Chapter Overview
13.2. Assumptions and Key Parameters 
13.3. Chinese Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.3.1. Scenario 1
13.3.2. Scenario 2
13.3.3. Scenario 3
13.3.4. Scenario 4

13.4. Conclusion

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030
14.3.1. Biopharmaceutical Contract Manufacturing Market in China for APIs, 2020-2030
14.3.2. Biopharmaceutical Contract Manufacturing Market in China for FDFs, 2020-2030

14.4. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Expression System Used
14.4.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mammalian Systems
14.4.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Microbial Systems
14.4.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Expression Systems

14.5. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Scale of Operation
14.5.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Preclinical / Clinical Scale Operations
14.5.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Commercial Operations

14.6. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Company Size
14.6.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Small Companies
14.6.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mid-sized Companies
14.6.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Large and Very Large Companies

14.7. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Type of Biologic
14.7.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Antibodies
14.7.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Vaccines
14.7.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Biologics

15 COVID-19 Impact on China Biopharmaceutical CMO Market
15.1. Chapter Overview
15.2. Current Opinions and Recuperative Initiatives of Key Players

15.2.1. WuXi AppTec
15.2.2. Boehringer Ingelheim
15.2.3. GE Healthcare
15.2.4. Lonza
15.2.5. AmbioPharm

15.2.6. Impact on China Biopharmaceutical Contract Manufacturing Market
 
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
16.7. Concluding Remarks

17. FUTURE OF THE CHINA BIOPHARMACEUTICAL CMO MARKET
17.1. Chapter Overview
17.2. Outsourcing Activities Anticipated to Increase in Future 
17.3. Shift from One-time Contracts to Strategic Partnerships
17.4. Adoption of Innovative Technologies
17.4.1. Single Use Bioreactors
17.4.2. Novel Bioprocessing Techniques
17.4.3. Bioprocess Automation

17.5. Growing Popularity of the Quality by Design Principle in Bioprocessing
17.6. Increasing Focus on Niche Therapeutic Areas
17.7. Biosimilars Market to Contribute to Contract Service Revenues
17.8. Capability and Facility Expansions to Establish One Stop Shop Expertise
17.9. Increase in Financial In-flow and Outsourcing Budgets

17.10. Challenges Faced by Sponsors and Service Providers
17.10.1. Concerns Associated with Single Use Systems
17.10.2. Issues Related to Capacity Fluctuations
17.11. Concluding Remarks
 
18. INTERVIEW TRANSCRIPTS
 
19. APPENDIX 1: TABULATED DATA
 
20. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

List Of Figures

Figure 3.1. Types of Biopharmaceuticals
Figure 3.2. Key Steps Involved in the Manufacturing of Biopharmaceuticals
Figure 3.3. Type of Third-Party Service Providers
Figure 3.4. Chinese Regulatory Scenario: Responsibilities of the Contract Giver
Figure 3.5. Chinese Regulatory Scenario: Responsibilities of the Contract Acceptor
Figure 3.6. Important Aspects of the Contract
Figure 3.7. Commonly Outsourced Operations
Figure 3.8. Key Factors to Consider while Selecting a CMO Partner
Figure 3.9. Risks and Challenges Associated with Contract Manufacturing
Figure 4.1. Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 4.2. Small Molecule versus Large Molecules: Comparison of Manufacturing Process
Figure 5.1. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Figure 5.2. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Figure 5.3. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Figure 5.4. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters
Figure 5.5. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Location of Manufacturing Facilities (Country-Wise)
Figure 5.6. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Product
Figure 5.7. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Services Offered
Figure 5.8. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic
Figure 5.9. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Figure 5.10. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Figure 5.11. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Figure 5.12. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Packaging Form Used
Figure 5.13. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Figure 6.1. JOINN Biologics: Development Services
Figure 6.2. WuXi Biologics: Annual Revenues, FY 2016 – FY 2019 (RMB Million)
Figure 6.3. WuXi of Biologics: Revenues by Regions of Operation, FY 2019 (RMB Million)
Figure 7.1. Recent Partnerships: Cumulative Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Partnership Model
Figure 7.3. Recent Partnerships: Year-wise Trend by Type of Partnership
Figure 7.4. Recent Partnerships: Distribution by Scale of Operation
Figure 7.5. Recent Partnerships: Distribution by Type of Biologic
Figure 7.6. Recent Partnerships: Distribution by Focus Area
Figure 7.7. Recent Partnerships: Distribution by Therapeutic Area
Figure 7.8. Recent Partnerships: Most Active Players
Figure 7.9. Geographical Distribution by Number of Partnerships
Figure 7.10. Geographical Distribution by Type of Partnership Model
Figure 7.11. Recent Partnerships: Intercontinental and Intracontinental Distribution
Figure 8.1. Recent Expansions: Cumulative Distribution by Year of Expansion, 2016-2020 (Till February)
Figure 8.2. Recent Expansions: Distribution by Type of Expansion
Figure 8.3. Recent Expansions: Distribution by Scale of Operation
Figure 8.4. Recent Expansions: Distribution by Type of Biologic
Figure 8.5. Recent Expansions: Distribution by Type of Biologic and Type of Expansion
Figure 8.6. Recent Expansions: Distribution by Location of Expansion Project
Figure 8.7. Recent Expansions: Distribution by Type of Expansion and Location of Facility
Figure 8.8. Recent Expansions: Distribution by Capacity of Expanded Facility (L)
Figure 8.9. Recent Expansions: Most Active Players
Figure 8.10. Geographical Distribution by Number of Expansion
Figure 8.11. Geographical Distribution by Type of Expansion
Figure 8.12. Geographical Distribution by Country
Figure 9.1. Clinical Trials: Distribution by Trial Registration Year (Cumulative Year-wise Trend)
Figure 9.2. Clinical Trials: Distribution of Active Trials by Trial Phase
Figure 9.3. Clinical Trials: Distribution by Trial Recruitment Status
Figure 9.4. Clinical Trials: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 9.5. Clinical Trial Analysis: Distribution by Geography
Figure 9.6. Clinical Trials: Distribution of Enrolled Patient Population by Geography
Figure 9.7. Clinical Trials: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 9.8. Clinical Trials: Distribution of Enrolled Patient Population in Active Trials by Trial Phase
Figure 9.9. Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 9.10. Clinical Trials: Most Active Industry Players (In Terms of Number of Registered Trials)
Figure 9.11. Clinical Trials: Most Active Non-Industry Players (In Terms of Number of Registered Trials)
Figure 9.12. Clinical Trials: Distribution by Clinical Trial Centers
Figure 10.1. Regional Distribution of Chinese Biopharmaceutical Contract Manufacturers by Location of Manufacturing Facilities
Figure 10.2. Regional Capability Analysis: Northern China
Figure 10.3. Regional Capability Analysis: Eastern China
Figure 10.4. Regional Capability Analysis: Eastern China
Figure 10.5. Regional Capability Analysis: Southern China
Figure 11.1. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Range of Installed Capacity
Figure 11.2. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Company Size
Figure 11.3. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Scale of Operation
Figure 11.4. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Type of Expression System Used
Figure 11.5. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Figure 11.6. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing Facility
Figure 11.7. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 12.1. Big Pharma Players in China: Distribution by Number of Biopharmaceutical Manufacturing Focused Initiatives
Figure 12.2. Big Pharma Players in China: Cumulative Distribution by Year of Initiative
Figure 12.3. Big Pharma Players in China: Distribution by Company and Year of Initiative
Figure 12.4. Big Pharma Players in China: Distribution by Type of Initiative
Figure 12.5. Big Pharma Players in China: Distribution by Type of Biologic
Figure 12.6. Big Pharma Players in China: Distribution by Company and Type of Biologic
Figure 12.7. Harvey Ball Analysis: Big Pharma Investment Summary
Figure 12.8. Big Pharma Players in China: Distribution by Location of Initiative
Figure 12.9. Big Pharma Players in China: Regional Distribution of Initiatives
Figure 12.10. Big Pharma Players in China: Distribution by Company and Location of Initiative
Figure 13.1. Make versus Buy Decision Making Framework
Figure 13.2. Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 14.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030 (USD Million)
Figure 14.2. Biopharmaceutical Contract Manufacturing Market in China for APIs, 2020-2030 (USD Million)
Figure 14.3. Biopharmaceutical Contract Manufacturing Market in China for FDFs, 2020-2030 (USD Million)
Figure 14.4. Biopharmaceutical Contract Manufacturing Market in China: Distribution by Type of Expression System Used, 2020, 2025 and 2030 (USD Billion)
Figure 14.5. Biopharmaceutical Contract Manufacturing Market in China: Share of Mammalian Systems, 2020-2030 (USD Billion)
Figure 14.6. Biopharmaceutical Contract Manufacturing Market in China: Share of Microbial Systems, 2020-2030 (USD Billion)
Figure 14.7. Biopharmaceutical Contract Manufacturing Market in China: Share of Other Expression Systems, 2020-2030 (USD Billion)
Figure 14.8. Biopharmaceutical Contract Manufacturing Market in China: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Billion)
Figure 14.9. Biopharmaceutical Contract Manufacturing Market in China: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Billion)
Figure 14.10. Biopharmaceutical Contract Manufacturing Market in China: Share of Commercial Operations, 2020-2030 (USD Billion)
Figure 14.11. Biopharmaceutical Contract Manufacturing Market in China: Distribution by Company Size, 2020, 2025 and 2030 (USD Billion)
Figure 14.12. Biopharmaceutical Contract Manufacturing Market in China: Share of Small Companies, 2020-2030 (USD Billion)
Figure 14.13. Biopharmaceutical Contract Manufacturing Market in China: Share of Mid-sized Companies, 2020-2030 (USD Billion)
Figure 14.14. Biopharmaceutical Contract Manufacturing Market in China: Share of Large / Very Large Companies, 2020-2030 (USD Billion)
Figure 14.15. Biopharmaceutical Contract Manufacturing: Distribution of Manufacturing Agreements Based on Type of Biologics and Geography
Figure 14.16. Biopharmaceutical Contract Manufacturing Market in China: Distribution by Type of Biologic, 2020, 2025 and 2030 (USD Billion)
Figure 14.17. Biopharmaceutical Contract Manufacturing Market in China: Share of Antibodies, 2020-2030 (USD Billion)
Figure 14.18. Biopharmaceutical Contract Manufacturing Market in China: Share of Vaccines, 2020-2030 (USD Billion)
Figure 14.19. Biopharmaceutical Contract Manufacturing Market in China: Share of Other Biologics, 2020-2030 (USD Billion)
Figure 15.1. Biopharmaceutical Contract Manufacturing Market in China, 2015-2030: COVID-19 Impact Informed Scenario (USD Billion)
Figure 16.1. Chinese Biopharmaceutical Contract Manufacturers: SWOT Analysis
Figure 16.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 4.1. Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 5.1. List of Chinese Biopharmaceutical Contract Manufacturers
Table 5.2. Chinese Biopharmaceutical Contract Manufacturers: Information on Scale of Operation
Table 5.3. Chinese Biopharmaceutical Contract Manufacturers: Information on Type of Product
Table 5.4. Chinese Biopharmaceutical Contract Manufacturers: Information on Type of Services Offered
Table 5.5. Chinese Biopharmaceutical Contract Manufacturers: Information on Type of Biologic
Table 5.6. Chinese Biopharmaceutical Contract Manufacturers: Information on Type of Expression System Used
Table 5.7. Chinese Biopharmaceutical Contract Manufacturers: Information on Type of Bioreactor Used
Table 5.8. Chinese Biopharmaceutical Contract Manufacturers: Information on Mode of Operation of Bioreactor
Table 5.9. Chinese Biopharmaceutical Contract Manufacturers: Information on Type of Packaging Form Used
Table 5.10. Chinese Biopharmaceutical Contract Manufacturers: Information on Regulatory Accreditations
Table 6.1. ChemPartner Biologics: Company Overview
Table 6.2. ChemPartner Biologics: Overview of Manufacturing Capabilities
Table 6.3. ChemPartner Biologics: Recent Developments and Future Outlook
Table 6.4. JHL Biotech: Company Overview
Table 6.5. JHL Biotech: Overview of Manufacturing Capabilities
Table 6.6. JHL Biotech: Recent Developments and Future Outlook
Table 6.7. JOINN Biologics: Company Overview
Table 6.8. JOINN Biologics: Overview of Manufacturing Capabilities
Table 6.9. MabPlex: Company Overview
Table 6.10. MabPlex: Overview of Manufacturing Capabilities
Table 6.11. MabPlex: Recent Developments and Future Outlook
Table 6.12. Mycenax Biotech: Company Overview
Table 6.13. Mycenax Biotech: Overview of Manufacturing Capabilities
Table 6.14. Mycenax Biotech: Recent developments and Future Outlook
Table 6.15. WuXi AppTec: Company Overview
Table 6.16. WuXi Biologics: Overview of Manufacturing Capabilities
Table 6.17. WuXi Biologics: Recent Developments and Future Outlook
Table 7.1. Chinese Biopharmaceutical Contract Manufacturers: List of Partnerships, 2016-2020
Table 8.1. Chinese Biopharmaceutical Contract Manufacturers: List of Expansions, 2016-2020
Table 10.1. Chinese Biopharmaceutical Contract Manufacturers: Regional Distribution by Type of Product
Table 11.1 China Biopharmaceutical Contract Manufacturers: Installed Capacity
Table 11.2. Capacity Analysis: Average Capacity based on Company Size (Sample Dataset)
Table 11.3. Capacity Analysis: Total Installed Capacity in China
Table 18.1. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Table 18.2. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Table 18.3. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Table 18.4. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters
Table 18.5. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Within China)
Table 18.6. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Location of Manufacturing Facilities (Country-Wise)
Table 18.7. Chinse Biopharmaceutical Contract Manufacturers: Distribution by Type of Product
Table 18.8. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Services Offered
Table 18.9. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic
Table 18.10. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Table 18.11. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Table 18.12. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Table 18.13. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Type of Packaging Form Used
Table 18.14. Chinese Biopharmaceutical Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Table 18.15. WuXi Biologics: Annual Revenues, FY 2016-FY 2019 (RMB Million)
Table 18.16. WuXi Biologics: Revenues by Regions of Operation, FY 2019 (RMB Million)
Table 18.17. Recent Partnerships: Cumulative Distribution by Year of Partnership
Table 18.18. Recent Partnerships: Distribution by Partnership Model
Table 18.19. Recent Partnerships: Year-wise Trend by Type of Partnership
Table 18.20. Recent Partnerships: Distribution by Scale of Operation
Table 18.21. Recent Partnerships: Distribution by Type of Biologic
Table 18.22. Recent Partnerships: Distribution by Focus Area
Table 18.23. Recent Partnerships: Distribution by Therapeutic Area
Table 18.24. Recent Partnerships: Most Active Players
Table 18.25. Geographical Distribution by Number of Partnerships
Table 18.26. Geographical Distribution by Type of Partnership Model
Table 18.27. Recent Partnerships: Intercontinental and Intracontinental Distribution
Table 18.28. Recent Expansions: Cumulative Distribution by Year of Expansion, 2016-2020 (Till February)
Table 18.29. Recent Expansions: Distribution by Type of Expansion
Table 18.30. Recent Expansions: Distribution by Sale of Operation
Table 18.31. Recent Expansions: Distribution by Type of Biologic
Table 18.32. Recent Expansions: Distribution by Type of Biologic and Type of Expansion
Table 18.33. Recent Expansions: Distribution by Location of Expansion Project
Table 18.34. Recent Expansions: Distribution by Type of Expansion and Location of Facility
Table 18.35. Recent Expansions: Distribution by Capacity of Expanded Facility (L)
Table 18.36. Recent Expansions: Most Active Players
Table 18.37. Geographical Distribution by Number of Expansions
Table 18.38. Geographical Distribution by Type of Expansion
Table 18.39. Recent Expansions: Geographical Distribution by Country
Table 18.40. Clinical Trials: Distribution by Trial Registration Year (Cumulative Year-wise Trend)
Table 18.41. Clinical Trials: Distribution of Active Trials by Trial Phase
Table 18.42. Clinical Trials: Distribution by Trial Recruitment Status
Table 18.43. Clinical Trials: Distribution by Trial Registration Year and Trial Recruitment Status
Table 18.44. Clinical Trials: Distribution by Geography
Table 18.45. Clinical Trials: Distribution of Enrolled Patient Population by Geography
Table 18.46. Clinical Trials: Distribution of Enrolled Patient Population by Trial
Table 18.47. Clinical Trials: Distribution of Enrolled Patient Population in Active Trials by Trial Phase
Table 18.48. Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 18.49. Clinical Trials: Most Active Industry Players (In terms of Number of Registered Trials)
Table 18.50. Clinical Trials: Most Active Non-Industry Players (In terms of Number of Registered Trials)
Table 18.51. Clinical Trials: Distribution by Clinical Trial Centers
Table 18.52. Regional Distribution of Chinese Biopharmaceutical Contract Manufacturers by Location of Manufacturing Facilities
Table 18.53. Chinese Biopharmaceutical Contract Manufacturers: Regional Distribution by Type of Product
Table 18.54. Regional Capability Analysis: Northern China
Table 18.55. Regional Capability Analysis: Eastern China
Table 18.56. Regional Capability Analysis: Central China
Table 18.57. Regional Capability Analysis: Southern China
Table 18.58. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Range of Installed Capacity
Table 18.59. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Company Size
Table 18.60. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Scale of Operation
Table 18.61. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Type of Expression System Used
Table 18.62. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Table 18.63. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing Facility
Table 18.64. Chinese Biopharmaceutical Contract Manufacturing Capacity: Distribution by Scale of Operation and Location of Manufacturing Facility
Table 18.65. Big Pharma Players in China: Distribution by Number of Biopharmaceutical Manufacturing Focused Initiatives
Table 18.66. Big Pharma Players in China: Cumulative Distribution by Year of Initiative
Table 18.67. Big Pharma Players in China: Distribution by Company and Year of Initiative
Table 18.68. Big Pharma Players in China: Distribution by Type of Initiative
Table 18.69. Big Pharma Players in China: Distribution by Type of Biologic
Table 18.70. Big Pharma Players in China: Distribution by Company and Type of Biologic
Table 18.71. Harvey Ball Analysis: Big Pharma Investment Summary
Table 18.72. Big Pharma Players in China: Distribution by Location of Initiative
Table 18.73. Big Pharma Players in China: Regional Distribution of Initiatives
Table 18.74. Big Pharma Players in China: Distribution by Company and Location of Initiative
Table 18.75. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030 (USD Billion)
Table 18.76. Biopharmaceutical Contract Manufacturing Market in China for APIs, 2020-2030 (USD Billion)
Table 18.77. Biopharmaceutical Contract Manufacturing Market in China for FDFs, 2020-2030 (USD Billion)
Table 18.78. Biopharmaceutical Contract Manufacturing Market in China: Distribution by Type of Expression System Used, 2020, 2025 and 2030
Table 18.79. Biopharmaceutical Contract Manufacturing Market in China: Share of Mammalian Systems, 2020-2030 (USD Billion)
Table 18.80. Biopharmaceutical Contract Manufacturing Market in China: Share of Microbial Systems, 2020-2030 (USD Billion)
Table 18.81. Biopharmaceutical Contract Manufacturing Market in China: Share of Other Expression Systems, 2020-2030 (USD Billion)
Table 18.82. Biopharmaceutical Contract Manufacturing Market in China: Distribution by Scale of Operation, 2020, 2025 and 2030 (USD Billion)
Table 18.83. Biopharmaceutical Contract Manufacturing Market in China: Share of Preclinical / Clinical Scale Operations, 2020-2030 (USD Billion)
Table 18.84. Biopharmaceutical Contract Manufacturing Market in China: Share of Commercial Scale of Operations, 2020-2030 (USD Billion)
Table 18.85. Biopharmaceutical Contract Manufacturing Market in China: Distribution by Company Size, 2020, 2025 and 2030 (USD Billion)
Table 18.86. Biopharmaceutical Contract Manufacturing Market in China: Share of Small Companies, 2020-2030 (USD Billion)
Table 18.87. Biopharmaceutical Contract Manufacturing Market in China: Share of Mid-sized Companies, 2020-2030 (USD Billion)
Table 18.88. Biopharmaceutical Contract Manufacturing Market in China: Share of Large and Very Large Companies, 2020-2030 (USD Billion)
Table 18.89. Biopharmaceutical Contract Manufacturing Market in China: Distribution by Type of Biologic, 2020, 2025 and 2030 (USD Billion)
Table 18.90. Biopharmaceutical Contract Manufacturing Market in China: Share of Antibodies, 2020-2030 (USD Billion)
Table 18.91. Biopharmaceutical Contract Manufacturing Market in China: Share of Vaccines, 2020-2030 (USD Billion)
Table 18.92. Biopharmaceutical Contract Manufacturing Market in China: Share of Others, 2020-2030 (USD Billion)
Table 18.93. Biopharmaceutical Contract Manufacturing Market in China, 2015-2030: COVID-19 Impact Informed Scenario (USD Billion)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3SBio
  2. ABL Bio
  3. AC Immune
  4. Adagene
  5. Adimmune
  6. Almirall 
  7. Alvotech
  8. Amaran Biotechnology
  9. AmbioPharm
  10. Amicus Therapeutics
  11. AMW
  12. Applied Biological Materials
  13. Aravive Biologics
  14. Arch Biopartners
  15. Arcus Biosciences
  16. AstraZeneca
  17. Asymchem Laboratories
  18. AutekBio
  19. Bayer
  20. BeiGene 
  21. Berkeley Lights
  22. Bioasis Technologies
  23. BioMarin Pharmaceutical
  24. BJ Bioscience
  25. Boehringer Ingelheim BioXcellence
  26. Boyalife
  27. Brii Biosciences
  28. CANbridge Pharmaceuticals
  29. Canton Biologics
  30. Beijing CC-Pharming
  31. Celltrion
  32. Changchun High & New Technology Industry
  33. ChemPartner
  34. Chime Biologics
  35. China Regenerative Medicine International
  36. Chinese Academy of Medical Sciences
  37. Chinese Peptide
  38. Chinese General Hospital
  39. CMAB Biopharma
  40. CPC Scientific
  41. CSBio
  42. EirGenix
  43. Eli Lilly
  44. Encure Biopharma
  45. EOC Pharma
  46. Etinpro
  47. Fapon Biopharma
  48. Fuda Cancer Hospital
  49. GE Healthcare
  50. GeneMedicine
  51. GeneQuantum Healthcare
  52. GenScript
  53. GlaxoSmithKline
  54. GreenPak Biotech
  55. Harbour BioMed
  56. Henlius Biotech
  57. Hile Bio-Technology
  58. Hong Kong Institute of Biotechnology
  59. Hummingbird Bioscience
  60. Hybio Pharmaceutical
  61. iBio
  62. I-Mab Biopharma
  63. Immune Pharmaceuticals
  64. IncoCell Tianjin
  65. Inhibrx
  66. IQVIA
  67. JHL Biotech
  68. Jiangsu Provincial Center for Disease Control and Prevention
  69. JOINN Biologics
  70. Kanda BioTech
  71. Levena Biopharma
  72. Lonza
  73. MabPlex
  74. Mab-Venture Biopharma
  75. MedImmune
  76. Merck Millipore
  77. Mycenax Biotech
  78. Nan Fung Group
  79. National Taiwan University Hospital
  80. Navrogen
  81. NBE-Therapeutics
  82. Novartis
  83. NovoCodex Biopharmaceuticals
  84. Oxford BioTherapeutics
  85. PaizaBio
  86. Pall Corporation
  87. Peking Union Medical College Hospital
  88. Pfizer
  89. Phanes Therapeutics
  90. Pharmadule Morimatsu
  91. Qilu Pharmaceutical
  92. Regulus Therapeutics
  93. Roche
  94. Samsung Bioepis
  95. Sandoz
  96. Sanofi
  97. ScinoPharm
  98. Shanghai Jiao Tong University 
  99. Shenzhen Geno-immune Medical Institute
  100. Shenzhen JYMed Technology
  101. Stellar Biotechnologies
  102. Sun Yat-sen University
  103. Suzhou Kintor Pharmaceuticals
  104. Taiwan Liposome Company
  105. Taron Solutions
  106. Therapure Biopharma
  107. Thermo Fisher Scientific
  108. ThermoGenesis
  109. Thousand Oaks Biopharmaceuticals
  110. Tsinghua University Innovation Center for Immune Therapy 
  111. UNC Lineberger Comprehensive Cancer Center
  112. Vectron Biosolutions
  113. Verseau Therapeutics
  114. Vir Biotechnology
  115. WuXi AppTec
  116. WuXi Biologics
  117. Yunfeng Capital
  118. Zai Lab
  119. Zhejiang Hisun Pharmaceutical
  120. Zhejiang Teruisi Pharmaceutical

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com